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Malignant melanoma originating from the urethra in
females is very aggressive with poor prognosis, and
accounts for 0.2% of all malignant melanomas and 4%
of urethral cancers [1]. In this case report, vesical invasion
of a large primary urethral malignant melanoma and
the need for cystectomy are discussed.
CASE PRESENTATION
A 75-year-old, non-smoking female presented at our
clinic with voiding dysfunction and a urethral mass.
Physical examination revealed a 4–5cm brown mass
covered with dirty yellowish material protruding
from inside urethra through the labia majora (Figure 1).
On abdominopelvic magnetic resonance imaging, a
mass extending from the urethra with dimensions of
4 × 2 cm, and periurethral heterogenous fatty planes
consistent with infiltration, were noted (Figure 2).
Since the histopathologic examination was consistent
with HMB45+ (melanoma antibody) malignant mela-
noma, cystourethrectomy, and bilateral inguinal and
pelvic lymphadenectomy were performed in one ses-
sion (Figure 3). The final pathology report revealed a
primary urethral malignant melanoma with a largest
diameter of 4.5 cm, which covered 3 cm2 of the infe-
rior bladder wall (Figure 4). The primary tumoral mass
was 1 mm away from the surgical margin. Histo-
pathological examination of the bilateral lymph nodes
(10 right-sided and 7 left-sided lymph nodes) stained
with hematoxylin/eosin and Mason-Fontana dyes did
not show any evidence of metastatic foci.
Postoperative adjuvant chemotherapy was not
deemed appropriate because of the patient’s cardio-
pulmonary morbidities and the presence of multiple
pulmonary metastases. The patient eventually died
13 months after surgery.
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We report a 75-year-old female with a primary urethral malignant melanoma. A mass protruding
from inside the urethra was detected on physical examination. Abdominopelvic magnetic reso-
nance imaging revealed a mass extending from the urethra with dimensions of 4 × 2 cm, and peri-
urethral heterogenous fatty planes consistent with infiltration. The histopathologic examination
was consistent with HMB45(+) malignant melanoma. We performed cystourethrectomy and
bilateral inguinal and pelvic lymphadenectomy in one session. The pathology report revealed
primary malignant melanoma of the urethra invading the inferior bladder wall. The patient
received no adjuvant therapy because of cardiopulmonary morbidities and the presence of multiple
pulmonary metastases. The patient eventually died 13 months after surgery.
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DISCUSSION
This rarely seen, primary malignant melanoma of the
urethra usually originates from the distal urethra [2].
The prognosis of urethral malignant melanoma is
worse than that of skin melanoma. The prognosis is
related to the time of the patient’s referral, delay in
diagnosis, depth and the level of invasion, and the
mitotic ratio. Other important etiologic factors affect-
ing prognosis is the failure to reach and excise ade-
quate surgical margins due to anatomic limitations [3].
Other approaches to manage urethral malignant
melanoma include partial or radical urethrectomy.
Partial urethrectomy is not considered adequate for
local control. DiMarco et al reported local recurrence
in six of seven patients who underwent partial ure-
threctomy with a minimum negative surgical margin 
of 2.5 mm [4]. In the present case a 0.1-cm negative
surgical margin was achieved. Because of the local
aggressiveness of malignant melanomas, a minimum
negative surgical margin of 2.5 cm is recommended
[5]. In some studies local recurrence was reportedly
increased to 100% after partial urethrectomy [6,7].
Considering these data, the length of the negative
surgical margin is thought to be an influential param-
eter on local recurrence and survival.
DiMarco et al concluded that none of the patients
who had undergone partial urethrectomy with subse-
quently detected recurrence had bladder involve-
ment. However, as reported in the literature, bulky
Figure 1. Mass expanding from inside the urethra and labia. Figure 2. Magnetic resonance imaging of the urethral mass and
bladder.
Figure 3. Cystourethrectomy material. Figure 4. Histologic assessment of the urethral malign
melanoma with vesical involvement (hematoxylin and eosin;
original magnification, 125×).
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(> 0.76 mm) malignant melanomas progress more rap-
idly with increasing rates of local recurrence and
metastases [8,9]. In our case a tumoral mass measuring
4.5 cm in diameter, and covered an area of 3 cm2 within
the muscular layer of the inferior vesical wall. This
finding suggests a positive correlation between the
size of the tumor and vesical invasion. Since the female
urethra is about 4–5 cm long, and considering the dif-
ficulty in achieving a sufficiently longer negative 
surgical margin during the resection of tumors with
larger diameters, radical cystourethrectomy might be
a preferred approach.
Local relapse and systemic metastases often de-
velop in the early postoperative period after surgery
for urethral malignant melanoma. Therefore, surgery
alone is not adequate to control local relapses and
systemic metastases, and effective postoperative adju-
vant therapy is required to prevent the progression of
the disease. Combined use of multiple chemotherapeu-
tic agents such as cisplatin, dacarbazine, carmustine,
and tamoxifen has been recommended in lieu of mono-
therapy [10]. However, even combination regimens do
not satisfactorily increase the survival rates of patients
with metastatic melanoma. Immunotherapy based 
on α-interferon and tumor vaccines has also been sug-
gested in recent studies [11]. Unfortunately, a chemo-
therapeutic regimen could not be administered to our
case because of the adverse cardiopulmonary side
effects.
In conclusion, because partial urethrectomy is
inadequate for local control of tumors, radical ure-
threctomy is recommended for the surgical treatment of
urethral malignant melanoma in females. Therefore,
cystourethrectomy should be considered based on
the possibility of vesical involvement, particularly in
females with larger urethral malignant melanomas.
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